GenSight Biologics SA (SIGHT) AI Stock Analysis

• Market Cap: €23.03M
• Dividend Yield: N/A
• Average Volume (3M): 616.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.69
• Revenue Growth: -92.35%
• EPS Growth: 63.25%
• Country: FR
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 173,543,100
• 10 Day Avg. Volume: 718,774
• 30 Day Avg. Volume: 616,456
• PEG Ratio: 0.03
• Price to Book (P/B): -0.96
• Price to Sales (P/S): 9.85
• P/FCF Ratio: -2.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.40
• Price Target Upside: 300.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: €0.14 ▲(37.00% Upside)

The overall stock score is primarily impacted by the company's challenging financial performance, marked by persistent losses and high leverage. Technical analysis suggests neutral to slightly bearish conditions, while valuation metrics reflect ongoing financial distress. The absence of earnings call data and corporate events leaves these areas unaddressed.

Positive Factors

Proprietary Gene Therapy Platform

The company's proprietary gene therapy platform provides a competitive edge in treating rare eye diseases, supporting long-term product development and potential market leadership.

Research Collaborations

Collaborations with academic and research institutions can enhance the company's R&D capabilities, leading to potential breakthroughs and sustained innovation in gene therapy.

High Gross Profit Margin

A consistently high gross profit margin indicates effective cost management and pricing power, which can contribute to long-term financial stability once revenue growth stabilizes.

Negative Factors

Persistent Losses

Ongoing losses and high leverage suggest financial instability, which may hinder the company's ability to invest in growth and sustain operations without external funding.

Negative Stockholders' Equity

Negative stockholders' equity indicates financial distress, limiting the company's ability to raise capital and posing a risk to long-term solvency.

Reliance on External Financing

Dependence on external financing for cash flow needs increases financial risk, as it may lead to unfavorable terms and affect the company's strategic flexibility.

GenSight Biologics SA Business Overview & Revenue Model

Company Description

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

How the Company Makes Money

GenSight Biologics generates revenue through a combination of product sales, licensing agreements, and research collaborations. The company primarily focuses on advancing its gene therapy products through clinical trials and obtaining regulatory approvals to commercialize its treatments. Significant revenue streams may include potential milestone payments from partnerships with larger pharmaceutical companies, as well as royalties from the sales of approved therapies. Additionally, GenSight may engage in collaborations with academic institutions and other research organizations to further its product pipeline, which can also contribute to its earnings.

GenSight Biologics SA Financial Statement Overview

Summary

GenSight Biologics SA is in a challenging financial position, characterized by persistent losses and high leverage. Despite some revenue growth, profitability and financial stability remain significant concerns. The company's financial health is heavily reliant on external financing, which poses risks in maintaining operations and pursuing growth opportunities.

Income Statement

GenSight Biologics SA has experienced inconsistent revenue trends over the years, with a notable revenue decline in 2021 and subsequent volatility. The gross profit margin is consistently high, but the company faces significant challenges in profitability, as evidenced by consistently negative net income and EBIT margins. The recent year shows improvement in revenue but still struggles with substantial losses, indicating ongoing financial challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is unfavorable due to negative equity, and return on equity is not meaningful under these circumstances. The equity ratio is also negative, highlighting a risky financial position with heavy reliance on debt.

Cash Flow

The cash flow statement indicates negative operating cash flow, but there has been improvement in free cash flow growth in recent years. However, the free cash flow to net income ratio is negative, reflecting ongoing operational challenges. The company relies heavily on financing activities to support its cash flow needs.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.63M	1.27M	2.58M	5.28M	4.39M
Gross Profit	2.63M	3.00M	2.58M	5.28M	4.39M
EBITDA	-14.76M	-21.73M	-26.77M	-25.52M	-34.13M
Net Income	-14.00M	-26.22M	-27.62M	-28.62M	-34.02M
Balance Sheet
Total Assets	10.76M	9.13M	25.94M	56.65M	47.36M
Cash, Cash Equivalents and Short-Term Investments	2.46M	2.13M	10.61M	44.29M	37.94M
Total Debt	19.11M	23.54M	12.65M	12.57M	14.45M
Total Liabilities	37.68M	39.83M	41.22M	40.66M	35.69M
Stockholders Equity	-26.92M	-30.67M	-15.28M	15.99M	11.75M
Cash Flow
Free Cash Flow	-12.94M	-24.67M	-34.01M	-17.17M	-15.05M
Operating Cash Flow	-12.94M	-24.66M	-33.75M	-17.14M	-15.04M
Investing Cash Flow	17.00K	209.00K	172.00K	-16.00K	-376.00K
Financing Cash Flow	13.54M	15.86M	95.00K	23.74M	33.86M

GenSight Biologics SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.13, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.58 is Neutral, neither overbought nor oversold. The STOCH value of 7.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:SIGHT.

GenSight Biologics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALDVI	49 Neutral	€24.65M	―	―	―	101.95%	35.55%
ALVAL	49 Neutral	€14.45M	-1.01	―	―	―	―
SIGHT	45 Neutral	€23.03M	-1.02	―	―	-92.35%	63.25%